Arthritis & Rheumatism, Volume 60,
October 2009 Abstract Supplement

The 2009 ACR/ARHP Annual Scientific Meeting
Philadelphia October 16-21, 2009.


Association of Anti-oxLDL/2 GP1 Immune Complex and Accelerated Atherosclerosis in Patients with Primary Antiphospholipid Syndrome

Barrera1,  Antonio, Hernandez2,  Claudia, Medina3,  Gabriela, Saavedra4,  Miguel, Jara3,  Luis Javier

Hospital de Especialidades Centro Medico La Raza IMSS, Mexico Distrito federal, Mexico
Hospital de Especialidades Centro Medico La Raza IMSS, Mexico, Mexico
Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico
Hospital Angeles Metropolitano, Mexico DF, Mexico

Purpose:

Autoantibodies against oxLDL/b2 GP1 complexes occur in patients with antiphospholipid syndrome (APS) and significantly correlate with arterial thrombosis, but their exact clinical significance in primary antiphospholipid syndrome (PAPS) and accelerated atherosclerosis remains unclear

Method:

We included 40 PAPS patients and 40 controls matched by age and gender. Demographic and clinical data were obtained by direct interview, chart review, and physical examination. Cardiovascular risk factors for atherosclerosis were registered. Blood samples from patients and controls were taken for serum determination of IgG, and IgM anti-oxLDL/b2GP1 antibodies (ELISA test, Immunomex commercial kit, normal values: < 20 IU). Atherosclerosis was defined as a carotid intima-media thickness (IMT) greater than 0.8 mm. measured by high resolution B mode ultrasound.

Results:

The mean age of patients and controls was 41 ± 6 years with a female predominance (93%), disease duration was 10 ± 5 years. The principal clinical manifestations of PAPS patients were deep venous thrombosis (50%) and cerebral vascular disease (36%). Traditional cardiovascular risk factors were similar in patients and controls. Patients with PAPS had a significant IMT in comparison with controls (0.75 ±.09 mm vs. 0.64 ± 0.09 mm, p < 0.001) and they had higher titers of anti-oxLDL/b2GP1 IgG in comparison with controls (67.62 ± 10.50 vs. 14.97 ± 18.01, p=0.005). In the group of patients with PAPS, there was not correlation between IgG anti-oxLDL/b2GP1 titers and IMT (r=-.182)

Conclusion:

Our study suggests that autoantibodies against oxLDL/b2GP1 complexes ocurr in patients with PAPS. However, there was not correlation between IgG anti-oxLDL/b2GP1 titers and IMT. Further prospective clinical studies are necessary to determine its role on aterosclerosis.

To cite this abstract, please use the following information:
Barrera, Antonio, Hernandez, Claudia, Medina, Gabriela, Saavedra, Miguel, Jara, Luis Javier; Association of Anti-oxLDL/2 GP1 Immune Complex and Accelerated Atherosclerosis in Patients with Primary Antiphospholipid Syndrome [abstract]. Arthritis Rheum 2009;60 Suppl 10 :1270
DOI: 10.1002/art.26344

Abstract Supplement

Meeting Menu

2009 ACR/ARHP